Price
Target price
-
-
-
-
-
?14.66
WKN: A2P26W / Symbol: CYCC / Name: Cyclacel Pharmaceuticals Inc. / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cyclacel Pharmaceuticals Inc. Stock
With 11 Sell predictions and only 2 Buy predictions the community sentiment for Cyclacel Pharmaceuticals Inc. is rather negative.
On the other hand, the target price of 14 € is above the current price of 0.22 € for Cyclacel Pharmaceuticals Inc., so the potential is actually 6263.64%.
Our community identified positive and negative aspects for Cyclacel Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "EBIT Margin" as a plus for the Cyclacel Pharmaceuticals Inc. stock. On the other hand our users think that "Expected Cash Flow" could be a problem in the future.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
Vaxart Inc. | -0.270% | 0.338% | -7.080% | 9.044% | 43.813% | -87.916% | - |
Larimar Therapeutics Inc. | - | -0.855% | -22.148% | 75.758% | 42.157% | -37.297% | -23.280% |
aTyr Pharma Inc | -2.530% | 1.316% | -10.465% | 12.409% | 19.380% | -79.189% | -48.667% |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat